Clinical trials: Treatment-Resistant Major Depressive Disorder
Treatment Resistant Depression, MDD
Psilocybin rTMS for Treatment Resistant Depression
The purpose of this study is to determine the safety and feasibility of sequencing psilocybin therapy with a short-duration, aiTBS protocol (Stanford Accelerated Intelligent Neuromodulation Therapy, or SAINT) in individuals with…
- Conditions
- Treatment Resistant Depression, MDD, Major Depressive Disorder, Recurrent Depression
- Trial name
- PSILOBSD (NCT06132178)
- Testing
- Psilocybin, Accelerated intermittent theta burst (aiTBS) rTMS treatment, Low-dose psilocybin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Texas at Austin
Depression - Major Depressive Disorder
Chart Review of Patients Undergoing Ketamine Treatments for Depression
The Ontario Ketamine and Infusion Centre (OKIC) is a CPSO-certified Level-II OHP and an outpatient centre for intravenous ketamine treatments for treatment-resistant depression.
- Trial name
- NCT07099235
- Testing
- ketamine hydrochloride
- Where
- Canada
- Volunteers
- 250 people
- Sponsor
- Sunnybrook Health Sciences Centre
Treatment Resistant Depression
Linear Asymmetric rTMS in Adolescent Treatment-Resistant Depression: Tolerability of Treatment Durations Ranging From Ten Days to One Day
This is a pilot interventional study to investigate the acceptability, tolerability, and side effect profile for varying numbers of treatment sessions/day of a new rTMS treatment in adolescents with treatment-resistant depression…
- Trial name
- NCT03986658
- Testing
- Linear Asymmetric rTMS System
- Where
- Canada
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- NeuroQore Inc.
Major Depressive Disorder
Intranasal Ketamine in Treatment-Resistant Depression
The objective of the current study is to investigate the safety and efficacy of a single dose of intranasal (IN) ketamine in treatment-resistant depression (TRD).
- Trial name
- NCT01304147
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- James Murrough
Treatment Resistant Depression
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain Stimulation (DBS) as an adjunctive treatment of non-psychotic…
- Trial name
- TRANSCEND (NCT06423430)
- Testing
- Active-stimulation
- Where
- 26 sites in United States
- Volunteers
- 100 people
- Sponsor
- Abbott Medical Devices
Major Depressive Disorder
Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)
One-third or more of individuals treated for major depressive disorder (MDD) do not experience remission of symptoms despite at least two adequate antidepressant trials.
- Trial name
- PAGE-1_AG1 (NCT01426516)
- Testing
- Genecept Assay
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Genomind, LLC
Resistant Major Depression
Study of Transcranial Direct Current Stimulation (tDCS) as add-on Treatment for Resistant Major Depression
The purpose of the study is to investigate the effect of tDCS applied at the anodic left DLPFC of patients with resistant depression compared to patients treated with conventional therapy.
- Trial name
- DEPRESCO (NCT01428804)
- Testing
- transcranial Direct Current Stimulation (tDCS)
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Unipolar Major Depression
Theta Burst Study Ghent
50 Right-handed antidepressant-free unipolar depressed patients (age 18-65 years) will be treated with in total 20 Theta burst sessions; these will be spread over 4 days.
- Trial name
- TBS Ghent (NCT01832805)
- Testing
- Theta burst stimulation.
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Ghent
Major Depressive Disorder
Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression
Aripiprazole has been approved by the FDA for augmenting ineffective/partially effective oral antidepressant therapy in patients suffering from major depression. The mechanism by which this augmentation is achieved is not known.
- Trial name
- NCT00953745
- Testing
- Escitalopram, Aripiprazole
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Depression - Major Depressive Disorder, Depression Bipolar
Mental Health Mission Mood Disorder Cohort Study
The current study aims to understand why some people with depression respond to treatment and others do not, using markers of clinical symptoms, both clinician reported outcome measures and patient reported outcome measures…
- Conditions
- Depression - Major Depressive Disorder, Depression Bipolar, Treatment Resistant Depression
- Trial name
- NCT07189689
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- University of Oxford
Treatment-resistant Depression, Major Depressive Disorder
Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression
In the past decades, the prevalence of adolescent depression and suicide increased significantly in Taiwan and worldwide. To date, the suicide mortality is the second mortality cause in the adolescent and young adult population…
- Trial name
- NCT05045378
- Testing
- Ketamine
- Where
- Taiwan
- Volunteers
- 12 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Major Depressive Disorder
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression
The purposes of this study are to determine: Whether olanzapine plus fluoxetine in combination will help patients with treatment-resistant major depression.
- Trial name
- NCT00035321
- Testing
- Olanzapine, Fluoxetine
- Where
- 33 sites in United States, Canada
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder, Insulin Resistance
Pioglitazone in Patients With Mood Disorders
The purpose of this study is to see how an insulin sensitizing medication, Pioglitazone, can cause changes in mood in some depressed patients. Study participants receive assessment of their cognitive and metabolic functioning.
- Trial name
- NCT01559857
- Testing
- Pioglitazone, Sugar Pill
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Stanford University
Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD).
- Trial name
- NORLIGHT (NCT07284667)
- Testing
- ACP-211
- Where
- 28 sites in United States
- Volunteers
- 153 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Major Depressive Disorder
Rapid Antidepressant Effects of Leucine
This randomized double-blind placebo-controlled crossover study seeks to evaluate the antidepressant effect of L-leucine, an essential amino acid, in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT03079297
- Testing
- L-Leucine, Maltodextrin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Texas Southwestern Medical Center
Major Depressive Disorder
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
This is a study that will recruit patients from the neurosurgery clinic and the regular TMS clinic. It's a smaller study designed to collect brain imaging pre-treatment and then use image guided TMS to treat patient with a one…
- Trial name
- NCT05813093
- Testing
- rTMS
- Where
- Canada
- Volunteers
- 88 people
- Sponsor
- Sunnybrook Health Sciences Centre
Depression
Ketamine Plus Lithium in Treatment-Resistant Depression
The purpose of this study is to test the antidepressant effect of ketamine when given repeatedly over a period of 1 week, as well as the use of Lithium as a relapse-prevention strategy for patients with treatment-resistant…
- Trial name
- NCT01880593
- Testing
- Lithium, Ketamine
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Depression
Effectiveness of Pramipexole for Treatment-Resistant Depression
This study will evaluate the effectiveness of pramipexole (Mirapex) in managing treatment-resistant depression.
- Trial name
- NCT00231959
- Testing
- Pramipexole (Mirapex)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Massachusetts General Hospital
Treatment Resistant Depression, Major Depressive Disorder
Clinical Study of GH001 in Depression
The aim of the study is to investigate the safety of GH001 (containing 5-methoxy-dimethyltryptamine; 5-MeO-DMT), and to investigate its effects on severity of depressive symptoms, and its dose-related psychoactive effects in…
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Depression
- Trial name
- NCT04698603
- Testing
- 5 Methoxy N,N Dimethyltryptamine
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- GH Research Ireland Limited
Depression - Major Depressive Disorder, Treatment Resistant Depression
ipRGC as a Potential Biomarker for Predicting Transcranial Magnetic Stimulation Treatment Response in Major Depressive Disorder
This research explores the potential of retinal ganglion cells (RGCs), particularly intrinsically photosensitive RGCs (ipRGCs), as biomarkers for predicting response to transcranial magnetic stimulation (TMS) in…
- Trial name
- BRIGHT (NCT07474974)
- Testing
- Repetitive transcranial magnetic stimulation (rTMS)
- Where
- Portugal
- Volunteers
- 44 people
- Sponsor
- Polytechnic Institute of Porto